In general, there appear to be two main mechanisms in dopamine treatment for GBM: inhibiting tumor angiogenesis through the VEGF pathway and inducing cell autophagy mediated by the mTOR pathway or via the Beclin1 (BECN1)-dependent pathway [190,191,192]. The gene discussed is MTOR; the disease is glioblastoma.